Kyverna Therapeutics (KYTX) Return on Capital Employed (2024 - 2026)
Kyverna Therapeutics posted quarterly Return on Capital Employed of 66.65% for Q1 2026, down 222.0% year-on-year from 54.63% in Q1 2025, and up 19.94% on a QoQ basis from 83.25% in Q4 2025.
Kyverna Therapeutics (KYTX) has 3 years of Return on Capital Employed data on file, last reported at 66.65% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 222.0% year-over-year to 66.65%; the trailing twelve-month figure through Mar 2026 stood at 66.65% (down 222.0% YoY), and the FY2025 full-year result was 64.63%, up 2668.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 66.65%, up from 83.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.45% in Q2 2024 and bottomed at 99.21% in Q3 2025.
- The 3-year median for Return on Capital Employed is 64.43% (2025), against an average of 61.36%.
- The widest annual swing landed in 2025, when Return on Capital Employed slumped 6081 bps; it then plunged 222 bps in 2026.
- A 3-year view of Return on Capital Employed shows it stood at 49.49% in 2024, then sank by 68 bps to 83.25% in 2025, then increased by 20 bps to 66.65% in 2026.
- The last three Return on Capital Employed figures came in at 66.65% (Q1 2026), 83.25% (Q4 2025), and 99.21% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -66.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.65% |
| Dec 31, 2025 | -83.25% |
| Sep 30, 2025 | -99.21% |
| Jun 30, 2025 | -84.22% |
| Mar 31, 2025 | -64.43% |
| Dec 31, 2024 | -49.49% |
| Sep 30, 2024 | -38.40% |
| Jun 30, 2024 | -28.45% |
| Mar 31, 2024 | -38.12% |